FluoroPharma Medical is a biopharmaceutical company engaged
in the discovery and development of proprietary positron emission tomography
(PET) imaging agents for the efficient detection and assessment of acute and
chronic forms of coronary artery disease (CAD). Currently, the company is
advancing two such product candidates in clinical trials – including CardioPET
and BFPet – which have been specially designed to rapidly target myocardial cells.
Upon commercialization, these innovative products are expected to enable more
accurate, early diagnosis of CAD, effectively facilitating improved treatment
options and better patient outcomes.
The market potential for a more effective diagnostic tool for
CAD is expansive. According to a report by the Centers for Disease Control and
Prevention, heart disease accounts for approximately 610,000 deaths in the
United States each year, making it the country’s leading cause of death. Among
these fatalities, approximately 47 percent occur as a result of heart attacks
outside of hospitals, suggesting that many people with CAD don’t receive proper
diagnosis. FluoroPharma is addressing this issue by developing molecular
imaging as a faster, more accurate approach to today’s standard test for
diagnosing CAD.
CardioPET is designed to address the current limitations of
CAD diagnostics. Upon commercialization, CardioPET is expected to be the first
commercially-available fatty acid analog marker in the U.S. and Europe, giving
FluoroPharma a noteworthy strategic advantage in the substantial diagnostic
markets of the two regions. Unlike currently available tools, a traceable fatty
acid analog marker will enable improved evaluation of cardiac blood flow and
the dietary preference of the cardiac muscle under stress and at rest, clearly
indicating the metabolic state of the heart and providing a more comprehensive
assessment of CAD.
“We are encouraged by our progress to date, and believe that
CardioPET potentially signals a compelling new direction for PET cardiac imaging
at a time when healthcare professionals around the world could benefit from
novel diagnostic imaging that expand and improve their diagnostic
capabilities,” Thijs Spoor, chairman and chief executive officer of
FluoroPharma, stated in a news release.
According to its most recent update, the company has
completed enrollment for its phase II clinical trial of CardioPET for the
assessment of CAD. This study, which is designed to assess the safety and
diagnostic performance of FluoroPharma’s innovative agent, marks a significant
step in the continued development of CardioPET. For prospective shareholders,
the company’s sustained progress toward the commercialization of its promising
development pipeline, in addition to the considerable marketability of its proprietary
diagnostic tools, could foreshadow an opportunity for FluoroPharma to achieve
sustainable returns in the months to come.
For more information, visit www.fluoropharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment